CN1612895A - 包含纤连蛋白ed-b结构域的特异抗体的缀合物和其在检测和治疗肿瘤中的应用 - Google Patents
包含纤连蛋白ed-b结构域的特异抗体的缀合物和其在检测和治疗肿瘤中的应用 Download PDFInfo
- Publication number
- CN1612895A CN1612895A CNA038019434A CN03801943A CN1612895A CN 1612895 A CN1612895 A CN 1612895A CN A038019434 A CNA038019434 A CN A038019434A CN 03801943 A CN03801943 A CN 03801943A CN 1612895 A CN1612895 A CN 1612895A
- Authority
- CN
- China
- Prior art keywords
- gly
- xaa
- seq
- ser
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
区域 | CDR长度(aa) | 序列 | 序列位置的最大(优选)变异 |
HCDR1 | 5 | SFSMS | 3(2,1) |
HCDR2 | 17 | SISGSSGTTYYADSVKG | 8(7,6,5,4,3,2,1) |
HCDR3 | 7 | PFPYFDY | 5(4,3,2,1) |
LCDR1 | 12 | RASQSVSSSFLA | 6(5,4,3,2,1) |
LCDR2 | 7 | YASSRAT | 4(3,2,1) |
LCDR3 | 10 | CQQTGRIPPT | 6(5,4,3,2,1) |
%剂量/g组织 | %剂量/g组织 | %剂量/g组织 | |
注射后1小时 | 注射后5小时 | 注射后24小时 | |
脾 | 1.97±0.018 | 0.53±0.07 | 0.31±0.08 |
肝 | 1.91±0.046 | 0.77±0.07 | 0.26±0.01 |
肾 | 19.21±0.70 | 4.35±0.082 | 1.32±0.10 |
肺 | 3.43±1.01 | 1.41±0.032 | 0.96±0.23 |
无内容物的胃 | 1.55±0.043 | 1.35±0.22 | 0.48±0.10 |
有内容物的小肠 | 1.42±0.10 | 1.26±0.34 | 0.29±0.05 |
肿瘤 | 10.72±3.21 | 5.13±1.45 | 3.48±1.28 |
血液 | 3.03±0.32 | 0.57±0.11 | 0.11±0.01 |
%剂量 | |
注射后24小时 | |
尿 | 80.63±3.33 |
粪便 | 3.94±0.17 |
%剂量/g组织 | |||
注射后1小时 | 注射后3小时 | 注射后24小时 | |
脾 | 1.94±0.49 | 1.28±0.13 | 1.18±0.24 |
肝 | 2.61±1.32 | 2.59±0.36 | 2.26±0.75 |
肺 | 1.52±1.57 | 2.36±0.30 | 0.76±0.21 |
无内容物的胃 | 1.44±0.81 | 1.40±0.31 | 0.65±0.28 |
有内容物的小肠 | 5.05±5.26 | 1.07±0.34 | 0.67±0.11 |
肿瘤 | 12.90±4.81 | 7.44±1.34 | 4.33±0.84 |
血液 | 5.55±1.89 | 1.80±0.20 | 0.11±0.02 |
注射后1小时 | 注射后3小时 | 注射后24小时 | |
肿瘤血液比率 | 2.76±2.00 | 4.16±0.75 | 36.36±3.78 |
Claims (21)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02000315.8 | 2002-01-03 | ||
EP02000315 | 2002-01-03 | ||
US35870202P | 2002-02-25 | 2002-02-25 | |
US60/358,702 | 2002-02-25 | ||
PCT/EP2003/000009 WO2003055917A2 (en) | 2002-01-03 | 2003-01-02 | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1612895A true CN1612895A (zh) | 2005-05-04 |
CN1612895B CN1612895B (zh) | 2010-05-12 |
Family
ID=26077560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN038019434A Withdrawn - After Issue CN1612895B (zh) | 2002-01-03 | 2003-01-02 | 包含纤连蛋白ed-b结构域的特异抗体的缀合物和其在检测和治疗肿瘤中的应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040001790A1 (zh) |
EP (2) | EP2239274A1 (zh) |
JP (2) | JP2005523887A (zh) |
CN (1) | CN1612895B (zh) |
AU (1) | AU2003210149B2 (zh) |
BR (1) | BR0306715A (zh) |
CA (1) | CA2468081A1 (zh) |
CY (1) | CY1110923T1 (zh) |
HK (1) | HK1076474A1 (zh) |
IL (2) | IL162201A0 (zh) |
MX (1) | MXPA04006517A (zh) |
NO (1) | NO20043246L (zh) |
PL (1) | PL369371A1 (zh) |
RU (1) | RU2352582C2 (zh) |
WO (1) | WO2003055917A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101287487B (zh) * | 2005-06-13 | 2013-02-06 | 西马生物医学计划公司 | 基于使用纤连蛋白eda结构域的试剂和方法 |
CN103275220A (zh) * | 2007-04-02 | 2013-09-04 | 菲洛根股份公司 | 与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原 |
WO2017084017A1 (zh) * | 2015-11-16 | 2017-05-26 | 合肥立方制药股份有限公司 | Ed-b蛋白在诊断组织增生中的应用 |
CN115666645A (zh) * | 2020-05-22 | 2023-01-31 | 菲洛根股份公司 | 用于脑瘤治疗的TNFα免疫缀合物疗法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
CA2400622A1 (en) | 2000-02-24 | 2001-08-30 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
IL154778A0 (en) * | 2000-09-07 | 2003-10-31 | Schering Ag | RECEPTOR IN THE EDb FIBRONECTIN DOMAIN |
MXPA04008810A (es) * | 2002-03-11 | 2005-09-08 | Philogen Spa | Marcado selectivo de vasculatura tumoral utilizando moleculas de anticuerpo. |
EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
ATE374367T1 (de) * | 2004-07-22 | 2007-10-15 | Bayer Schering Pharma Ag | Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind |
US20060039863A1 (en) * | 2004-07-22 | 2006-02-23 | Michael Schirner | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
JP2009535372A (ja) * | 2006-05-03 | 2009-10-01 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 抗edbフィブロネクチンドメイン抗体l19−sip及び抗−egfr−抗体の組合せ |
EP2036576A1 (en) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | ED-B fibronectin as stratification marker for antitumor drugs |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
US9603954B2 (en) | 2009-07-22 | 2017-03-28 | Actinium Pharmaceuticals Inc. | Methods for generating radioimmunoconjugates |
WO2011078250A1 (ja) * | 2009-12-25 | 2011-06-30 | 独立行政法人理化学研究所 | 生体内にて標的組織に指向する放射標識化合物およびその利用 |
WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
CN104215668A (zh) * | 2014-08-25 | 2014-12-17 | 浙江大学 | 基于theed纤维阵列的二氧化碳传感器及其制备方法 |
IL310865A (en) * | 2016-10-17 | 2024-04-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
CN117980326A (zh) | 2021-07-14 | 2024-05-03 | 2赛文缇生物公司 | 与来自抗体的结合结构域融合的经工程化的t细胞受体 |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2125854T3 (es) * | 1989-08-09 | 1999-03-16 | Rhomed Inc | Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio. |
EP1514934B1 (en) * | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US6171578B1 (en) * | 1999-04-14 | 2001-01-09 | Diatide, Inc. | Benzodiazepine derivatives for imaging thrombi |
CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
CA2400622A1 (en) | 2000-02-24 | 2001-08-30 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
-
2003
- 2003-01-02 BR BR0306715-7A patent/BR0306715A/pt not_active Application Discontinuation
- 2003-01-02 IL IL16220103A patent/IL162201A0/xx unknown
- 2003-01-02 MX MXPA04006517A patent/MXPA04006517A/es active IP Right Grant
- 2003-01-02 EP EP10162295A patent/EP2239274A1/en not_active Withdrawn
- 2003-01-02 JP JP2003556447A patent/JP2005523887A/ja not_active Withdrawn
- 2003-01-02 WO PCT/EP2003/000009 patent/WO2003055917A2/en active Application Filing
- 2003-01-02 CN CN038019434A patent/CN1612895B/zh not_active Withdrawn - After Issue
- 2003-01-02 EP EP03726977A patent/EP1461360B1/en not_active Expired - Lifetime
- 2003-01-02 CA CA002468081A patent/CA2468081A1/en not_active Withdrawn
- 2003-01-02 AU AU2003210149A patent/AU2003210149B2/en not_active Revoked
- 2003-01-02 RU RU2004123785/13A patent/RU2352582C2/ru not_active IP Right Cessation
- 2003-01-02 PL PL03369371A patent/PL369371A1/xx unknown
- 2003-01-03 US US10/336,041 patent/US20040001790A1/en not_active Abandoned
-
2004
- 2004-05-27 IL IL162201A patent/IL162201A/en not_active IP Right Cessation
- 2004-08-02 NO NO20043246A patent/NO20043246L/no unknown
-
2005
- 2005-09-22 HK HK05108339.8A patent/HK1076474A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 JP JP2009129965A patent/JP4663020B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-17 CY CY20101101038T patent/CY1110923T1/el unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101287487B (zh) * | 2005-06-13 | 2013-02-06 | 西马生物医学计划公司 | 基于使用纤连蛋白eda结构域的试剂和方法 |
CN103275220A (zh) * | 2007-04-02 | 2013-09-04 | 菲洛根股份公司 | 与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原 |
CN103275220B (zh) * | 2007-04-02 | 2016-01-20 | 菲洛根股份公司 | 与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原 |
WO2017084017A1 (zh) * | 2015-11-16 | 2017-05-26 | 合肥立方制药股份有限公司 | Ed-b蛋白在诊断组织增生中的应用 |
CN108291915A (zh) * | 2015-11-16 | 2018-07-17 | 合肥立方制药股份有限公司 | Ed-b蛋白在诊断组织增生中的应用 |
CN115666645A (zh) * | 2020-05-22 | 2023-01-31 | 菲洛根股份公司 | 用于脑瘤治疗的TNFα免疫缀合物疗法 |
US11872288B2 (en) | 2020-05-22 | 2024-01-16 | Philogen S.P.A. | TNF-alpha immunoconjugate therapy for the treatment of brain tumors |
Also Published As
Publication number | Publication date |
---|---|
NO20043246L (no) | 2004-08-02 |
WO2003055917A3 (en) | 2003-12-24 |
CY1110923T1 (el) | 2015-06-10 |
EP2239274A1 (en) | 2010-10-13 |
HK1076474A1 (en) | 2006-01-20 |
IL162201A (en) | 2011-04-28 |
AU2003210149B2 (en) | 2008-10-09 |
JP4663020B2 (ja) | 2011-03-30 |
EP1461360A2 (en) | 2004-09-29 |
RU2352582C2 (ru) | 2009-04-20 |
JP2009209149A (ja) | 2009-09-17 |
BR0306715A (pt) | 2004-12-28 |
US20040001790A1 (en) | 2004-01-01 |
EP1461360B1 (en) | 2010-08-18 |
RU2004123785A (ru) | 2005-08-10 |
PL369371A1 (en) | 2005-04-18 |
WO2003055917A2 (en) | 2003-07-10 |
CA2468081A1 (en) | 2003-07-10 |
AU2003210149A1 (en) | 2003-07-15 |
CN1612895B (zh) | 2010-05-12 |
IL162201A0 (en) | 2005-11-20 |
MXPA04006517A (es) | 2005-03-31 |
JP2005523887A (ja) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1612895A (zh) | 包含纤连蛋白ed-b结构域的特异抗体的缀合物和其在检测和治疗肿瘤中的应用 | |
CN1187374C (zh) | 人源化的特异于人4-1bb的抗体和含有它的药物组合物 | |
CN1317303C (zh) | 抗人腱生蛋白单克隆抗体 | |
CN1604966A (zh) | 直接靶定的结合蛋白 | |
CN1308448C (zh) | 低分子化的tpo激动剂抗体 | |
CN1308447C (zh) | 低分子化的激动剂抗体 | |
CN1229391C (zh) | 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体 | |
CN1250571C (zh) | 用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及其用途 | |
CN1202128C (zh) | 修饰蛋白的免疫原性 | |
CN101035809A (zh) | 抗tag-72的人源化单克隆抗体 | |
CN1878790A (zh) | 可中和的hgf表位和与其结合的中和抗体 | |
CN1492768A (zh) | 具有降低的免疫原性的人工蛋白质 | |
CN1509293A (zh) | 用于含杂合同种型抗体部分的蛋白质的表达技术 | |
CN1522264A (zh) | 抗cd40单克隆抗体 | |
CN1809592A (zh) | 识别n-乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用 | |
CN101074261A (zh) | Trail受体1和/或trail受体2特异性抗体及其应用 | |
CN1422333A (zh) | 诱导细胞凋亡的多肽 | |
CN1596313A (zh) | 人源化的胶原抗体及相关方法 | |
CN1918295A (zh) | 增强抗体活性的方法 | |
CN1639195A (zh) | 应用抗体分子对肿瘤血管进行选择性定向 | |
CN1642983A (zh) | 抗C5aR抗体及其应用 | |
CN1849144A (zh) | 使用放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管 | |
CN1703240A (zh) | LFA-1α亚基抗体及使用方法 | |
CN1151377C (zh) | 诊断及治疗鳞状细胞癌的方法 | |
CN1225479C (zh) | 肿瘤坏死因子抗体,其制备方法以及药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Inventor Correct: Hilger Christoph-stepan False: Fourth inventor Moosmayer Dieter Number: 18 Volume: 21 |
|
CI02 | Correction of invention patent application |
Correction item: Inventor Correct: Hilger Christoph-stepan False: Fourth inventor Moosmayer Dieter Number: 18 Page: The title page Volume: 21 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: THE FOURTH INVENTOR MOOSMAYER DIETER TO: FRANZ LUTZ |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR; FROM: THE FOURTH INVENTOR MOOSMAYER DIETER TO: FRANZ LUTZ |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076474 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1076474 Country of ref document: HK |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20100512 Effective date of abandoning: 20110921 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20100512 Effective date of abandoning: 20110921 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
C56 | Change in the name or address of the patentee |
Owner name: BAYER PHARMA AG Free format text: FORMER NAME: SCHERING AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Berlin Patentee after: Bayer Pharma AG Address before: Berlin Patentee before: Schering AG |